

**CHEMICALS (SHRI M.S. GURUPADASWAMY):** (a) No, Sir.

(b) and (c). Do not arise.

**Committee on Recovery of Overcharged Amount**

1231. SHRI KALPNATH SONKAR: Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) whether Government had set up a committee to determine the overcharged amounts recoverable under Drugs Prices Equalisation Account from the drug companies which had gone to the Supreme Court;

(b) if so, the names of the members of the Committee;

(c) the findings of the committee and the final amounts worked out against each company; and

(d) the action taken so far on these findings and when the process of recovery would be completed?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M.S. GURUPADASWAMY): (a) and (b). A Special Team consisting of the following members was constituted to determine the amount recoverable from the companies involved in Supreme Court case:—

- (1) Shri S. Guria,  
Deputy Secretary,  
Department of Chemicals and Petrochemicals
- (2) Shri R.N. Tandon,  
Joint Director (Chemicals)  
Department of Chemicals and Petrochemicals
- (3) A representative from BICP

(4) Shri Ashok Chopra,  
Junior Investigator,  
Department of Chemicals and Petrochemicals.

(c) and (d). The assessments made by the Special Team are being scrutinised and a decision in this regard will be taken shortly.

**Increase in Prices of Bulk Drugs and Formulations**

1232. SHRI KALPNATH SONKAR: Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) whether under the Drugs (Price Control) Order, 1987 even in respect of decontrolled bulk drugs and formulations, prior intimation to Government is obligatory before increasing the prices;

(b) if so, the names of such bulk drugs and formulations for which prices have been increased after the promulgation of DPCO, 1987; and

(c) the prices of these drugs and formulations at the commencement of DPCO, 1987 and at present and the percentage increase?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M.S. GURUPADASWAMY): (a) Yes, Sir. Under Para 11(2) of DPCO, 1987, any manufacturer who desires to market a new pack or revise the prices of an existing pack, of a non-scheduled formulation may do so after furnishing the details of the proposed retail price and cost data in Form 2-A.

(b) and (c). There is a very large number of bulk drugs and formulations running into thousands in the market. On account of this, the volume and labour involved will not be commensurate with the results likely to be